Book a Demo
Platform Overview
Features
Cardiac Amyloidosis Heart Failure Aortic Stenosis Pulmonary Hypertension Strain Stress Echocardiography
Operations
Operational Impact Deployment & Security Integrations Core Lab Solutions EHR Mining Partnerships
Tools
ROI Calculator Reimbursements Peer Comparison Regulatory Status
Library & news
Clinical Evidence Case Studies News
Our Story Careers Media Kit

Australia Reimbursement for AI Echocardiography

Coding and reimbursement pathways in Australia for echocardiography under the Medicare Benefits Schedule (MBS): Group I1 Subgroup 7 items for initial, serial, and stress echo, plus the CSANZ Level 2 requirements for billing stress items.

See all markets

Reimbursement Landscape in Australia

Echocardiography in Australia is reimbursed through the Medicare Benefits Schedule (MBS), administered by Services Australia under the Department of Health and Aged Care. Echo items sit under Group I1, Subgroup 7. Indication, requester type, and prior study history determine which item is billable.

MBS Group I1, Subgroup 7

Echo items 55126 through 55146 cover initial, serial, paediatric, fetal, and stress transthoracic echocardiography. Item selection depends on whether the study is initial, serial for a defined indication, or stress.

Frequency & Indication Rules

Most TTE items carry a 24-month frequency rule unless a specific clinical indication (heart failure, cardiomyopathy, valvular dysfunction, paediatrics, pericardial disease) allows more frequent serial studies.

CSANZ Level 2 for Stress

Stress echocardiography items (55141, 55143, 55145, 55146) require the reporting specialist to hold CSANZ Level 2 (or equivalent) certification in stress echocardiography.

Relevant Coding

MBS items in Group I1 Subgroup 7 covering echocardiography in Australia.

MBS
55126

Initial TTE

Real-time TTE with colour flow Doppler, at least three acoustic windows. Once per 24 months unless a serial indication applies.

Scheduled fee: AUD $264.90 (effective 1 July 2025). Any practitioner can request 55126, which makes it the workhorse for new-presentation echocardiograms. AI-assisted measurement and reporting augments the specialist interpretation within this item.

Scheme MBS Group I1, Subgroup 7
Scheduled fee (1 Jul 2025) $264.90 (85% benefit $225.20)
Requester Any practitioner
Frequency Once per 24 months (default)
Source mbsonline.gov.au
MBS
55127 / 55128

Serial TTE for Valvular Disease

55127 serial TTE for known valvular dysfunction with full quantitative assessment. 55128 same indication when requested by a rural GP in an MMM 3 to 7 area.

Scheduled fee: AUD $264.90 each (effective 1 July 2025). 55127 requires a specialist requester; 55128 extends access for rural / remote GPs (Modified Monash Model 3 to 7) to support rural cardiology pathways.

Scheme MBS Group I1, Subgroup 7
Scheduled fee (1 Jul 2025) $264.90 each
Requester Specialist (55127) / Rural GP MMM 3 to 7 (55128)
Source mbsonline.gov.au
MBS
55129 / 55132 / 55133

Serial TTE for Heart Failure, Paediatrics, Pericardial

55129 serial TTE for heart failure or cardiomyopathy. 55132 serial TTE in patients under 17 years or with complex congenital heart disease. 55133 frequent-repetition TTE for pericardial conditions or PBS medication monitoring.

Scheduled fees (1 July 2025): 55129 and 55132 at AUD $264.90; 55133 at AUD $238.40. These items recognise clinical scenarios where the 24-month frequency rule on 55126 is inappropriate. Serial heart failure echocardiography is a particularly high-volume use case for AI-assisted EF and strain quantification.

Scheme MBS Group I1, Subgroup 7
Scheduled fees (1 Jul 2025) $264.90 (55129/55132) · $238.40 (55133)
Requester Specialist (55133 any practitioner)
Source mbsonline.gov.au
MBS
55134 / 55137

Rare Repeat and Fetal Echocardiography

55134 repeat TTE for rare cardiac pathologies, once per 24 months. 55137 fetal echocardiography for suspected congenital abnormality.

Scheduled fee: AUD $264.90 each (effective 1 July 2025). Both items require a specialist requester. Fetal echocardiography sits within obstetric / maternal-fetal medicine referral pathways.

Scheme MBS Group I1, Subgroup 7
Scheduled fee (1 Jul 2025) $264.90 each
Requester Specialist
Source mbsonline.gov.au
MBS
55141 / 55143 / 55145 / 55146

Stress Echocardiography

55141 exercise stress echo with ECG. 55145 new pharmacologic stress echo. 55143 repeat pharmacologic stress echo. 55146 additional pharmacologic stress echo (governed by EMSR).

Scheduled fees (1 July 2025): 55141 exercise stress and 55143 repeat pharmacologic stress at AUD $472.20; 55145 new pharmacologic stress and 55146 additional pharmacologic stress at AUD $547.30. All stress items require the reporting specialist to hold CSANZ Level 2 certification in stress echocardiography (or recognised equivalent). AI-assisted strain and EF support pre- and peak-stress interpretation.

Scheme MBS Group I1, Subgroup 7
Scheduled fees (1 Jul 2025) $472.20 (55141/55143) · $547.30 (55145/55146)
Requester Specialist (CSANZ Level 2)
Source mbsonline.gov.au

Scheduled fees shown reflect the 1 July 2025 MBS indexation. Medicare benefit payable is 75 percent in-hospital, 85 percent out-of-hospital, and 95 percent under bulk-billing arrangements. The Extended Medicare Safety Net (EMSN) may apply for out-of-pocket totals once thresholds are reached. Private health insurance may pay above MBS for in-hospital studies depending on policy. Verify against the live MBS Online schedule and current Department of Health and Aged Care advice.

Model the impact on your service

Enter your annual echo volume and the relevant MBS scheduled fees to estimate net new capacity and Medicare benefits from AI-assisted reporting.

Reimbursement by Care Setting

MBS items pay differently across out-of-hospital, in-hospital private, and public hospital settings; private health insurance adds a fourth pathway.

Out-of-Hospital MBS

Bulk-billed and direct-billed studies in community cardiology clinics. Medicare pays 85 percent of the MBS scheduled fee, or 100 percent under bulk-billing.

Benefit 85 percent of MBS fee (100 percent bulk-billed)
Safety net EMSN may apply once thresholds reached
Typical items 55126, 55127, 55129, 55141, 55145

Community cardiology and rural cardiology pathways (55128 in particular) are a strong fit for AI-assisted reporting to lift throughput and reduce report turnaround.

In-Hospital (Private)

Studies performed on an admitted private patient. Medicare pays 75 percent of the MBS fee; private health insurance covers the gap up to its agreed schedule.

Benefit 75 percent of MBS fee (Medicare)
Top-up Private health insurer per policy schedule
Agreements Hospital purchaser provider agreements may apply

Private hospital cardiology services often hold purchaser-provider agreements with insurers that fix gap or no-gap arrangements above MBS.

Public Hospital

Public hospital cardiology services are funded by state and territory governments (Activity Based Funding) rather than MBS per study.

Funding State / territory ABF (National Efficient Price)
Recording ICD-10-AM / ACHI procedure coding
Value lever Throughput and length of stay

AI-assisted echo in this setting supports throughput within the public funding envelope rather than incremental per-study payment.

Australian Procurement & Regulatory Context

AI echocardiography software is assessed against TGA registration and Australian privacy requirements alongside the clinical and financial case.

TGA Registration

Software classified as a medical device requires inclusion on the Australian Register of Therapeutic Goods (ARTG). Us2.ai is registered as a Class IIb medical device under ARTG entry 382110.

Australian Privacy Principles

The Privacy Act 1988 and Australian Privacy Principles (APP) govern patient data handling. In-country (Australian Sovereign) cloud hosting is available for Australian customers when required by state or hospital policy.

State Health Procurement

State and territory Local Health Districts (LHD / HHS) run their own digital health procurement pathways. ISO 27001 certification and existing state health framework agreements support faster procurement.

Frequently Asked Questions

Common questions about Australian echocardiography MBS items and reimbursement.

Which MBS item should I bill for an initial TTE?
Item 55126 covers an initial transthoracic echocardiogram with colour flow Doppler and at least three acoustic windows. It is restricted to one study per patient every 24 months unless a specific serial indication applies (heart failure, valvular dysfunction, paediatrics, pericardial disease, rare repeat).
What are the current MBS scheduled fees for echocardiography?
Per the 1 July 2025 MBS indexation: the TTE family (55126 initial; 55127/55128 valvular serial; 55129 heart failure serial; 55132 paediatric serial; 55134 rare repeat; 55137 fetal) is AUD $264.90 per study. 55133 (frequent-repetition pericardial / PBS monitoring) is $238.40. Stress echo 55141 (exercise) and 55143 (repeat pharmacologic) are $472.20; 55145 (new pharmacologic) and 55146 (additional pharmacologic, EMSR) are $547.30. Benefit payable is 75% in-hospital, 85% out-of-hospital, 95% bulk-billed. (Source: MBS Online.)
What is the 24-month rule and which items override it?
MBS item 55126 (and 55134) apply a 24-month frequency rule. Serial-indication items (55127 valvular, 55129 heart failure / cardiomyopathy, 55132 paediatric / complex congenital, 55133 pericardial / PBS monitoring) recognise scenarios where more frequent follow-up is clinically appropriate.
What is CSANZ Level 2 and why does it matter?
The Cardiac Society of Australia and New Zealand (CSANZ) Level 2 in stress echocardiography is the credentialing requirement for the reporting specialist on stress echo items (55141, 55143, 55145, 55146). Without Level 2, an MBS stress echo item cannot be billed.
How does rural / remote billing work (55128)?
Item 55128 is the same indication as 55127 (serial TTE for valvular dysfunction) but recognises a rural GP requester in Modified Monash Model (MMM) areas 3 to 7. This supports timely follow-up echocardiography for rural patients without requiring specialist re-referral.
Are there Australian-specific codes for AI echocardiography?
As of the current MBS schedule, there is no Australia-specific item that corresponds to the US Category III CPT code for AI-assisted heart failure detection. AI-assisted reporting sits within the existing TTE and stress echo items; the value case is throughput, report turnaround, and report quality.
Is Us2.ai registered with the TGA?
Yes. Us2.ai is included on the Australian Register of Therapeutic Goods as a Class IIb medical device under ARTG entry 382110. See the Regulatory Status page for full clearance and certificate detail.
What about data sovereignty?
Australian-region cloud hosting is available, and on-premise deployment is supported for hospitals with stricter data residency or network-isolation requirements. Us2.ai is APP-compliant and holds ISO 27001:2022 and SOC 2 Type II certifications.
Where can I get Australia-specific reimbursement guidance?
Our team can provide detail tailored to community cardiology clinics, private hospital cardiology services, and state Local Health Districts, including current MBS context, TGA documentation, and supporting clinical evidence. Contact us for Australia-specific guidance.

Important Information

The information provided on this page is intended for general informational purposes only and is not a guarantee of coverage or reimbursement. MBS items, scheduled fees, frequency rules, and indications are subject to change. Providers should verify against the live MBS Online schedule and current Department of Health and Aged Care advice. This information does not constitute legal, financial, or billing advice. MBS is administered by Services Australia under the Department of Health and Aged Care.

Questions about Australia Reimbursement?

Our team can support business cases for community cardiology clinics, private hospital cardiology services, and state Local Health Districts with current MBS context, TGA documentation, and clinical evidence.

Contact Us